Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort

Caroline Papeix; Sandra Vukusic; Romain Casey; Nadine Debard; Bruno Stankoff; Serge Mrejen; Zoe Uhry; Eric Van Ganse; Anne Castot; Michel Clanet; Catherine Lubetzki; Christian Confavreux; For the TYSEDMUS and OFSEP Group

doi:10.1212/NXI.0000000000000297

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

1323

Article Figures & Data

Figures

Tables
Additional Files

Download figure

Open in new tab

Download powerpoint

Figure 1 Patient population included in the TYSEDMUS database
Natalizumab (NZ) >3: strictly more than 3 NZ infusions; pregnancy (0): no pregnancy during the year after NZ stop; Expanded Disability Status Scale (EDSS) M0 and M12: EDSS score available the month of the last NZ infusion and at 12 months after NZ discontinuation.
Download figure

Open in new tab

Download powerpoint

Figure 2 Instantaneous relapse rate per person-year after first natalizumab (NZ) stop (year) (n = 715)
Black line: instantaneous relapse rate estimation. Red lines: instantaneous relapse rate 95% confidence interval. Blue line: the end of the study (1 year after NZ stop).

Additional Files

Figures
Tables

Data Supplement

Files in this Data Supplement:

Figure e-1 - Microsoft Word file
Table e-1 - Microsoft Word file
Coinvestigators

Files in this Data Supplement:

Coinvestigators - Microsoft Word file
Coinvestigators - Microsoft Word file

Letters: Rapid online correspondence

No comments have been published for this article.

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
Submit only on articles published within 6 months of issue date.
Do not be redundant. Read any comments already posted on the article prior to submission.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.nn.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Topics Discussed

Alert Me

Alert me when eletters are published

Main menu

User menu

Search

Risk of relapse after natalizumab withdrawal

Results from the French TYSEDMUS cohort

Citation Manager Formats